$OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Sean Bohen
CEO
96
Employees
$13.67
Current Price
$1.78B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $951,502.52 | 40,000 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $951,502.52 | 40,000 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Mitchell Shawnte CHIEF LEGAL OFFICER | Sale | 15,000 | $23.01 | $345,150.00 | View Details |
| Mar 4, 2026 | Mitchell Shawnte CHIEF LEGAL OFFICER | Sale | 24,767 | $24.25 | $600,599.75 | View Details |
| Mar 4, 2026 | Mitchell Shawnte CHIEF LEGAL OFFICER | Sale | 233 | $24.69 | $5,752.77 | View Details |
24 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.51
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.51
Actual-$0.50
Beat
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: